Comparative Pharmacology
Head-to-head clinical analysis: ARISTOGEL versus CORTIFOAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTOGEL versus CORTIFOAM.
ARISTOGEL vs CORTIFOAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy; binds to androgen receptors, activating gene transcription and increasing protein synthesis.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Aristogel is a topical gel containing 1% testosterone. The recommended adult dose is 5 g (50 mg testosterone) applied once daily to clean, dry, intact skin of shoulders, upper arms, and/or abdomen. Apply at approximately the same time each day, preferably in the morning.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
None Documented
None Documented
Terminal elimination half-life is 12 hours. Given dosing frequency, steady-state achieved within 2 days; accumulation minimal with standard dosing.
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Primarily renal (80%) as unchanged drug; 20% fecal via biliary elimination.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Category C
Category C
Corticosteroid
Corticosteroid